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Background: Little is known about the knowledge, perceptions and prevention practices of the French general
population with respect to Hepatitis B virus (HBV) infection. This article describes this population’s knowledge of
HBV, their perceptions of the disease, and associated screening and vaccination practices. It compares these
indicators with those observed in the same population for HIV, an infection with a chronic course and transmission
modes resembling those of HBV.
Methods: A module on hepatitis B was added into the HIV KABP (Knowledge, Attitudes, Beliefs and Practices)
survey which was carried out telephonically in 2010 among a random sample of 9,014 individuals aged between
18–69 and living in metropolitan France.
Results: Compared with HIV, the general population was less aware that needle exchange during intravenous drug
use and sexual relationships are HBV transmission modes (HBV: 89.9% and 69.7%; HIV: 99.1% and 99.4%). The fear of
both illnesses was similar at 20.3%. The individual perceived risk of infection was higher for HBV than for HIV with,
respectively, 60.8% and 40.3% of respondents believing they had an equal or greater risk of being infected than the
average person. However, the percentage of those reporting HBV screening during their lifetime (27.4%) was half
that for HIV screening (61.4%). In multivariate analysis, HBV screening was reported more often by individuals born
in areas with high HBV endemicity (OR = 2.1 [95% CI: 1.5-2.9]) than by those born in low HBV endemicity areas, and
more often by those who reported they had taken drugs intravenously during their lifetime (OR = 2.2 [95% CI:
1.2-4.2]) than those who did not report such behavior. Almost one in two respondents (47%) reported HBV
vaccination. The intermediate or high endemicity groups did not report vaccination more often than those born in
low endemicity areas nor did those reporting intravenously drug use compared with those who did not.
Conclusions: This study highlights very contrasting levels of knowledge, perceptions and practices regarding HBV
and HIV in the French general population. Our results demonstrate the need to improve the general and high-risk
populations’ knowledge of HBV, in particular concerning sexual transmission, in order to improve screening and
vaccination practices.* Correspondence: c.brouard@invs.sante.fr
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Hepatitis B is a vaccine-preventable infection. It can be
transmitted sexually, by blood, from mother to child
during childbirth and by family contact [1]. For the most
part asymptomatic, patients can nevertheless develop
serious liver conditions (cirrhosis, hepatocellular carci-
noma) which sometimes lead to death. Worldwide,
chronic hepatitis B virus (HBV) infection concerns 370
million people, that is 5% to 7% of the world’s popula-
tion, and is responsible for more than 500,000 deaths
per year [1].
France is a country with low HBV endemicity, the
prevalence for chronic infection in 2004 being estimated
at 0.65% in the general population aged between 18–80
years old [2]. An estimated 1,300 deaths were attribut-
able to the disease annually [3]. In France, the following
principal factors are associated with HBV infection: be-
ing born in a country where there is an intermediate or
high HBV endemicity [4], intravenous drug use, defining
oneself as homosexual and being in an economically and
socially vulnerable situation [2]. Migrants represent ap-
proximately 8% of the general French metropolitan
population (i.e. mainland France and the island of
Corsica). A quarter of these migrants come from coun-
tries where HBV endemicity is high (14% Asia, 12% Sub
Saharan Africa) [5]. Accordingly, HBV screening and
vaccination are recommended for those at highest risk,
notably sexual partners, close family and friends of
HBV-infected individuals (whether acute or chronic),
people who have multi-partner sexual relationships, mi-
grants originating from areas with a high level of endem-
icity, parenteral drug users, health professionals, and
others [6-8]. Moreover screening has been obligatory for
pregnant women since 1992 [9], and vaccination has
been recommended for infants since 1995 with a catch-
up vaccination recommended for children and adoles-
cents [6].
Despite the continued increase in hepatitis B screening
since the 2000s [10], its efficacy remains insufficient. In
2004, more than one in two chronically infected persons
were unaware of their status [2]. Moreover, anti-HBV
vaccination coverage has remained low, especially since
1998, due to the suspicion of a link between anti-HBV
vaccination and demyelinating diseases [11]. In 2003–4
and 2010, coverage was estimated at 42% for 15-year-old
adolescents and 65% for 24-month-old children, respec-
tively [12].
Although the principal epidemiological indicators are
well documented, French [13-15] and international data
[16,17] on the general population’s knowledge, perceptions
and practices regarding hepatitis B are very fragmented.
Yet these same indicators are essential for a better under-
standing of the mechanisms which can hinder or drive
prevention behaviors and improve public health policy.Accordingly, the addition of a section on hepatitis B to the
KABP 2010 survey, which focused primarily on the know-
ledge, attitudes, believes and practices of the French gen-
eral population regarding HIV [18], provided us with the
opportunity to measure, for the first time, these indicators
for hepatitis B.
The objective of this paper is to present the French
general population’s knowledge of the transmission modes
of HBV, their perceptions regarding the disease and their
practices with respect to screening and vaccination, by
comparing these indicators with those for HIV, as the
transmission modes and chronic evolution of the two dis-
eases closely resemble each other.
Methods
The KABP 2010 survey, approved by the National Data
Protection Authority, was carried out anonymously over
the telephone after oral consent for participation in the
study [18]. Selection of the individual to be interviewed
was carried out by random sampling in two phases: after a
random generation of two samples of telephone numbers -
one landline, the other mobile - one individual was ran-
domly drawn from all the eligible people in that household
(landline) or from all the eligible principal users of that
phone number, if there was more than one user (mobile).
All persons who could speak French, were aged between
18 and 69 and resident in metropolitan France were
eligible. In order to take into account the probability of
being selected and to keep the structure similar to that of
the national population, the sample was first weighted for
numbers of eligible adults in households and for the distri-
bution of listed and unlisted landline and mobile phones.
It was then adjusted for sociodemographic data gathered
in the 2006 national census.
The data collected for hepatitis B, just as those col-
lected for HIV/AIDS, focused on the interviewed per-
son’s knowledge of transmission modes, perceptions and
fears regarding these infections, knowledge of someone
in his/her circle of family or friends being infected by
HBV or HIV, and whether he/she had been screened for
HBV or HIV or vaccinated against HBV. These indica-
tors reflecting knowledge, perceptions and practices
regarding HBV were compared with those for HIV. Fur-
thermore the following indicators were examined in
multivariate analysis using logistic regression: “having a
good level of knowledge on the transmission modes of
HBV”, “considering oneself to be at a higher risk of HBV
contamination with respect to the average person”, “self-
reported screening for HBV during one’s lifetime”, and
“self-reported vaccination against HBV during one’s life-
time”. A good level of knowledge about the transmission
modes of HBV was defined as providing a correct re-
sponse to each of the following four questions: answering
“yes” for the three questions worded as “Can transmission
Table 1 Socio-demographic characteristics of the sample,
KABP survey, France, 2010
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“when sharing a needle during drug injection?”, and “dur-
ing pregnancy?” and answering “no” to the item “Can
transmission occur from a mosquito bite?”.
Individuals were grouped according to the level of en-
demicity of HBV in their country of birth [4]. Having
taken drugs intravenously was defined as reporting to have
injected drugs at least once during one’s lifetime. Analyses
were carried out using the Stata® 11.0 statistical software
package (Stata Corporation, College Station, TX).45–54 1,916 22.8
55-69 2,058 19.4
Educational Level
No educational qualification 989 11.2
CAP/BEP/BEPC (vocational diplomas) 2,744 31.9
Secondary school certificate 1,687 19.1Results
Final rates of participation for the survey were 67.2%
and 65%, for landline and mobile phones respectively. In
total, 9,014 people were interviewed: 5,012 on a landline
and 4,002 on a mobile phone. The principal characteris-
tics of the sample are outlined in Table 1.Higher education qualification 3,573 37.8
Net monthly income per household
<2,000 € 2,821 31.0
2,000–2,999 € 2,696 29.9
≥ 3,000 € 3 311 37.0
Did not wish to share this
information/ Did not know
186 2.1
Area of residence




Living in a couple or a stable relationship
No 2,117 21.9
Yes 6,883 78.1








1 raw data. Some data were missing for age (n = 1), educational level (n = 21),
living in couple or a stable relationship (n = 14) and country of birth (n = 3).
2 weighted and adjusted data.
3 Countries with a low level of endemicity (prevalence of HBsAg <2%):
Metropolitan France, Northern and Western European countries, North America,
Pacific Islands; countries with an intermediate level of endemicity (prevalence of
HBsAg between 2 and 8%): French Overseas Administrative Districts and
territories, Eastern and Southern Europe, North Africa, the Middle-East, the Indian
subcontinent, South America; countries with a high level of endemicity
(prevalence of HBsAg > 8%): Sub-Saharan Africa, Asia.Knowledge
Among the people interviewed, 96.1% declared having
already heard of hepatitis B. Amongst these, 89.9% knew
that HBV can be transmitted by needle-sharing while
taking drugs, 79.1% that transmission can occur during
pregnancy and 69.7% that transmission can occur during
unprotected sexual intercourse (Table 2). Women were
more aware of the possibility of transmission during
pregnancy than men (81.3% vs. 76.6%, p < 10-3). The 18–
30 year-old (74.6%) and 31–44 year-old (73.4%) popula-
tions were more aware of sexual transmission than was
the 45–69 year-old population (63.9%, p < 10-3).
Transmission by sexual relations and intravenous
drug-use was less known for HBV (69.7% and 89.9%)
than for HIV (99.4% and 99.1%). The proportion of
those declaring “not to know” about these two transmis-
sion modes was higher for HBV (approximately 4%) than
for HIV (approximately 0.2%). The proportion of people
incorrectly stating that transmission was possible from a
mosquito bite was similar for both diseases (HBV: 26%;
HIV: 24.5%). In total, 46.5% of those interviewed correctly
responded to these three questions (i.e. sexual relations,
intravenous drug use and mosquito-bite transmission) re-
garding HBV versus 72.3% for HIV. This proportion fell to
38.4% when the survey question regarding “transmission
of HBV during pregnancy” was taken into account.
In multivariate analysis, a good level of knowledge of
HBV transmission modes was found more often in women
than in men, in the 18–30 year-old population than in the
45–54 and 55–69 year-old populations, in people who had
educational qualifications (compared with those without
qualifications), in those whose net monthly household in-
come was greater than 3,000 Euros (compared with less
than 2,000 Euros), in those who did not live in a couple or
in a stable relationship, and in those who reported to knowsomeone infected with HBV in their circle of family and
friends (Table 3).
It should be noted that the percentage of respondents
reporting to know someone in their circle of family and
Table 2 Main reported indicators of knowledge, perceptions and behaviors with regard to HBV and HIV/AIDS, KABP
survey, France, 2010
Hepatitis B HIV/AIDS
(n = 9,014) (n = 9,014)
% (95% CI) % (95% CI)
Knowledge of transmission modes1
Believing that Hepatitis B/AIDS transmission is possible:
during unprotected sexual intercourse (1) 69.7 (68.6-70.8) 99.4 (99.2-99.6)
through the sharing of needles while injecting drugs2 (2) 89.9 (89.2-90.6) 99.1 (98.9-99.3)
from mosquito bite (3) 26.0 (25.0-27.1) 24.5 (23.5-25.5)
during pregnancy (4) 79.1 (78.1-80) −4
% of correct answers to questions (1), (2) and (3) 3 46.5 (45.3-47.6) 72.3 (71.3-73.3)
% of correct answers to questions (1), (2), (3) and (4) 3 38.4 (37.2-39.5) −4
Knowing someone in circle of family and friends who was infected 5
Yes 21.4 (20.5-22.3) 12.6 (11.9-13.4)
Perhaps - 8.8 (8.2-9.4)
No 77.3 (76.3-78.2) 78.4 (77.5-79.3)
Did not know 1.3 (1.1-1.6) 0.16 (0.08-0.3)
Perceptions
Fear of the disease (Viral hepatitis / AIDS) for oneself
Very 9.8 (9.1-10.5) 13.4 (12.6-14.2)
Quite 10.5 (9.8-11.2) 6.9 (6.3-7.4)
Not very 39.4 (38.3-40.5) 24.6 (23.6-25.6)
Not at all 39.5 (38.4-40.6) 55.1 (54.0-56.3)
Did not know 0.8 (0.6-1.0) 0.04 (0.01-0.11)
Perception of the risk of contracting Hepatitis B /HIV with respect to the average person
Greater risk 7.6 (7.0-8.2) 3.8 (3.4-4.2)
Similar risk 53.2 (52.1-54.4) 36.5 (35.4-37.6)
Less risk 29.9 (28.9-31.0) 37.5 (36.4-38.7)
No risk 7.4 (6.8-8.0) 21.9 (21.0-22.9)
Did not know 1.9 (1.6-2.4) 0.3 (0.2-0.4)
Practices
Hepatitis B /HIV screening during one’s lifetime
Yes, once 17.4 (16.6-18.3) 31.5 (30.4-32.5)
Yes, more than once 10.0 (9.4-10.7) 29.9 (28.8-31.0)
No 67.8 (66.7-68.8) 38.1 (37.0-39.2)
Did not know 4.8 (4.3-5.2) 0.5 (0.4-0.7)
Hepatitis B vaccination
Yes 47.0 (45.9-48.2) -
No 43.9 (42.8-45.1) -
Did not know 9.0 (8.4-9.7) -
95% CI: 95% confidence interval.
1Only those people who reported that they had already heard of hepatitis B (n = 8,686) were asked questions about knowledge of hepatitis B transmission modes; all
participants in the study group were asked all other questions (n = 9,014).
2The wording of questions was different depending on the virus, as follows: “Sharing a needle while injecting drugs” for HBV and “When injecting using a needle that
has already been used” for HIV.
3The correct answer was “yes” for questions (1), (2) and (4) and “no” for question (3).
4 These questions were not asked for HIV.
5 The wording of questions was different depending on the virus, as follows: “Do you personally know one or more people in your circle of family and friends who
currently has or who had Hepatitis B?” / “Do you personally know one or more people in your circle of family and friends who is seropositive or who has AIDS?. The
choice of answers was also different (yes, no, did not know for HBV; yes, perhaps, no, did not know for HIV).
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Table 3 Factors associated with a good level of
knowledge about HBV transmission modes1, KABP
survey, France, 2010 (multivariate analysis)
% Adjusted OR CI 95%
Gender
Men 35.1 1
Women 41.4 1.3 1.2-1.5
Age (in years)
18–30 42.6 1
31–44 42.5 1.0 0.9-1.1
45–54 34.9 0.8 0.6-0.9
55-69 30.0 0.6 0.5-0.7
Educational level
No educational qualification 26.1 1
CAP/BEP/BEPC (vocational diplomas) 32.8 1.3 1.1-1.6
Secondary school certificate 38.6 1.5 1.2-1.8
Higher education qualification 46.2 2.0 1.6-2.4
Net monthly income per household
<2,000 € 35.5 1
2,000–2,999 € 37.1 1.0 0.9-1.2
≥ 3,000 € 42.3 1.2 1.1-1.3
Did not wish to share this









Living in a couple or a stable relationship
No 39.9 1
Yes 38.0 0.9 0.8-0.98
Knowing someone in circle of family
and friends who was infected
No 37.4 1
Yes 41.9 1.2 1.1-1.3
HBV endemicity in country of birth2
Low 38.7 1
Intermediate or high 35.7 0.9 0.8-1.1
Intravenous drug use in one’s lifetime
No 38.4 1
Yes 29.0 0.8 0.4-1.6
95% CI: 95% confidence interval.
1A good level of knowledge was defined as providing the correct response to the 4
questions asked about HBV transmission modes, as follows: “yes” for the items
“sexual relations without a condom”, “through the sharing of needles while injecting
drugs”, and “during pregnancy”; “no” for the item “from a mosquito bite”.
2 See the footnote 3 in Table 1.
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than that found for HIV (12.4%) (Table 2). This propor-
tion was greater for those respondents born in zones ofintermediate or high HBV endemicity than for those born
in zones of low endemicity (25.0% vs. 21.0%, p < 0.05). It
was also greater for those who declared intravenous drug
use during their lifetime than for those who did not
(36.1% vs. 21.3%, p < 0.05).
Perceptions
Among the various risks and diseases which participants
reported that they were “quite” or “very” afraid of, viral
hepatitis and AIDS yielded similar results (20.3%). These
values were in fifth position after cancer (59.4%), road
accidents (58.7%), senile dementia (39.8%) and heart dis-
ease (38.8%), and before sexually transmissible diseases
(excluding HIV) (17.3%) and tuberculosis (11.6%). Never-
theless, the proportion of those not having any fear about
HIV (55.1%) was higher than that for viral hepatitis
(39.5%) (Table 2).
With, respectively, 7.6% and 53.2% of respondents
considering they had “a greater risk than” and “the same
risk as” the average person of being contaminated by
HBV (vs. 3.8% and 36.5% respectively for HIV), the per-
ception of the risk of contamination was higher for HBV
than for HIV (Table 2). In multivariate analysis, the factors
associated with considering oneself more at risk of HBV
contamination than the average person were: being aged
between 31–44 or 45–54 (in contrast to 18–30), having
no educational qualification, not living in a couple or in a
stable relationship and knowing someone infected with
HBV (Table 4). Perception of being at a greater risk than
the average person was not associated with the level of
knowledge of HBV transmission modes.
Screening and vaccination practices
Hepatitis B screening
Just over a quarter of respondents declared that they had
been screened for hepatitis B during their lifetime (17.4%
on one occasion, 10.0% on more than one occasion) com-
pared with 61.4% for AIDS (31.5% on one occasion, 29.9%
on more than one occasion) (Table 2). Although women
did not report screening for HBV more often than men
(27.8% and 27.1% respectively), those women with at least
one child born after 1992 (the year when obligatory HBV
screening during pregnancy was implemented in France)
reported screening more often than did those with no child
born after 1992 (32.9% vs. 24.3%, p < 10-4). The younger
the last child, the higher was this proportion, reaching
39.9% in women who had a child less than one year old.
Reporting previous hepatitis B screening increased with in-
creasing HBV endemicity in the country of birth, from
26.8% to 30.1% and 45.1% for those born, respectively, in
low, intermediate and high endemicity zones.
Multivariate analysis highlighted that reporting to have
been screened for hepatitis B was more frequent in the
following situations: as the educational level achieved
Table 4 Factors associated with the perception of being at
greater risk of HBV infection with respect to the average
person, KABP survey, France, 2010 (multivariate analysis)
% Adjusted OR CI 95%
Gender
Men 7.7 1
Women 7.4 0.9 0.8-1.1
Age (in years)
18–30 5.1 1
31–44 8.4 1.7 1.3-2.3
45–54 10.8 2.2 1.7-2.9
55-69 5.5 1.0 0.7-1.3
Educational level
No educational qualification 9.8 1
CAP/BEP/BEPC (vocational diplomas) 7.9 0.7 0.5-0.95
Secondary school certificate 5.8 0.6 0.4-0.8
Higher education qualification 7.5 0.7 0.5-0.9
Net monthly income per household
<2,000 € 7.4 1
2,000–2,999 € 7.5 1.1 0.9-1.4
≥ 3,000 € 7.5 1.1 0.8-1.4
Did not wish to share this







district (which includes Paris)
7.4 0.9 0.8-1.2
Living in a couple or a stable relationship
No 8.3 1
Yes 7.3 0.8 0.6-0.95
Knowing someone in circle of family
and friends who was infected
No 6.9 1
Yes 9.9 1.5 1.2-1.8
Having a good level of knowledge
about HBV transmission modes
No 7.4 1
Yes 7.9 1.1 0.9-1.3
HBV endemicity in country of birth1
Low 7.5 1
Intermediate or high 8.3 1.1 0.8-1.4
Intravenous drug use in one’s lifetime
No 7.6 1
Yes 7.9 0.7 0.2-2.4
95% CI: 95% confidence interval.
1 See the footnote 3 in Table 1.
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with the 18–30 year-old one), in those who considered
themselves at greater risk than the average person, in
those who knew an infected person, in those born in
areas with high HBV endemicity (when compared with
those born in low endemicity areas), in those who de-
clared intravenous drug use in their lifetime and in inhabi-
tants of Île-de-France administrative district (Table 5). It
was also associated with a good level of knowledge of
transmission modes and with the fact of reporting to be
vaccinated against HBV.
Amongst those who reported that they had already
been screened, 3.7% [95% CI: 2.9-4.5%] reported that
they currently had or previously had hepatitis B (men:
4.2%: women: 3.2%; p > 0.05). This proportion increased
with age (1.8%, 2.4%, 4.2% and 9.1%, respectively, for
the 18–30, 31–44, 45–54 and 55–69 year-old popula-
tions, p < 10-4) and with the level of HBV endemicity in
the country of birth (3.4%, 4.8%, 9.5% respectively for
low, intermediate and high endemicity levels, p < 10-2). It
was also higher in people who declared intravenous drug
injection in their lifetime than in those who did not
(28.6% vs. 3.5%, p < 10-4).
Vaccination against hepatitis B
Almost half of the respondents (47%) declared that they
had been vaccinated against hepatitis B (irrespective of
the number of vaccination doses administered) while
9.0% declared that they did not know if they had been
vaccinated or not (Table 2). Independently of the other
factors, anti-HBV vaccination was more frequently re-
ported by women, by the 18–30 year-old population
(with respect to higher age groups), by people with an
educational level equal to or higher than a secondary
school certificate (with respect to those with no educa-
tional qualification), by those who believed themselves
to be at greater risk of contamination than the average
person and by those who declared that they had been
screened during their lifetime (Table 5). It was not sig-
nificantly associated with the level of HBV endemicity in
the country of birth or with intravenous drug injection
during one’s lifetime.
Discussion
This study enabled us to document, for the first time in
France, the knowledge, perceptions and practices of the
general population with regard to hepatitis B and to
compare these same factors with those for HIV. Al-
though, as our results show, the transmission modes for
the former were certainly less known than those for the
latter – especially regarding HBV infection through sexual
transmission, unknown to 1 in 3 respondents - the fear of
viral hepatitis seemed to be as strong as that of HIV and
the perception of the risk of contamination with respect
Table 5 Factors associated with HBV screening during one’s lifetime and anti-HBV vaccination, KABP survey, France,
2010 (multivariate analysis)
HBV screening Anti-HBV vaccination
% Adjusted OR CI 95% % Adjusted OR CI 95%
Gender
Men 27.1 1 45.1 1
Women 27.8 0.95 0.9-1.1 48.9 1.2 1.1-1.3
Age (in years)
18–30 26.0 1 62.3 1
31–44 32.6 1.3 1.2-1.5 54.5 0.7 0.6-0.7
45–54 26.5 1.2 0.97-1.4 36.4 0.3 0.3-0.4
55-69 21.7 1.1 0.9-1.3 27.4 0.2 0.2-0.3
Educational level
No educational qualification 18.2 1 33.7 1
CAP/BEP/BEPC (vocational diplomas) 23.4 1.4 1.04-1.6 41.3 1.1 0.9-1.3
Secondary school certificate 26.1 1.5 1.1-1.8 49.5 1.2 1.01-1.5
Higher education qualification 34.2 1.8 1.5-2.3 54.4 1.5 1.2-1.8
Net monthly income per household
<2,000 € 25.6 1 45.8 1
2,000–2,999 € 26.6 0.9 0.8-1.1 47.4 1.0 0.9-1.2
≥ 3,000 € 30.4 0.9 0.8-1.1 48.2 1.0 0.9-1.2
Did not wish to share this information/ Did not know 16.2 0.6 0.4-0.9 40.5 0.9 0.6-1.3
Area of residence
Outside the Ile-de-France administrative district 26.2 1 46.1 1
Ile-de-France administrative district (which includes Paris) 32.5 1.2 1.04-1.3 50.9 1.0 0.9-1.2
Living in a couple or a stable relationship
No 25.4 1 48.0 1
Yes 28.1 1.1 0.98-1.3 46.8 1.0 0.9-1.2
Knowing someone in circle of family and friends who was infected
No 23.7 1 46.5 1
Yes 41.1 2.1 1.9-2.4 49.0 1.0 0.9-1.2
Having a good level of knowledge about HBV transmission modes
No 23.9 1 44.3 1
Yes 33.6 1.4 1.3-1.6 51.7 1.1 0.97-1.2
Perception of being at greater risk of HBV infection with respect to the average person
No 25.6 1 45.5 1
Yes 50.1 2.5 2.1-3.1 66.1 2.2 1.8-2.7
HBV endemicity in country of birth1
Low 26.8 1 46.8 1
Intermediate 30.1 1.2 0.9-1.4 47.3 1.1 0.9-1.4
High 45.1 2.1 1.5-2.9 56.1 1.2 0.8-1.6
Intravenous drug use in one’s lifetime
No 27.4 1 47.0 1
Yes 45.6 2.2 1.2-4.2 52.1 1.2 0.6-2.4
HBV screening during one’s lifetime
No - - - 40.3 1
Yes 64.8 2.4 2.2-2.7
Anti-HBV vaccination
No 18.3 1 - - -
Yes 37.8 2.4 2.2-2.7
95% CI: 95% confidence interval.
1 See the footnote in Table 1.
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than the latter. It is true that today, in France, the epi-
demiological context is less favorable to HBV than to HIV
with, respectively, an estimated prevalence of 280,000
infected people [2] versus 152,000 [19]. However, in the
present study, the proportion of those reporting to have
been screened for HBV during their lifetime was less than
half that for HIV (27% vs. 61%).
The contrasting results found in the present study for
these two infections whose characteristics (transmission
modes, chronic course) are closely related, can be partly
explained by the exceptional communication of the issues
surrounding HIV, in particular the large scale worldwide
media prevention campaigns right from the moment of its
discovery. Despite two successive national prevention pro-
grams (2002–2005, 2009–2012 [20]) and several informa-
tion campaigns (documents, website, movies…) targeted
to migrants and men who have sex with men, communica-
tion campaigns on HBV and resources allocated to HBV
remained modest in comparison with HIV. The fact that
a vaccination exists for HBV but not for HIV may also
play a part in some of the differences observed, notably
the lower levels of reported HBV screening. Nevertheless,
multivariate analyses on the associations between know-
ledge, perceptions and practices regarding HBV high-
lighted results which were very close to those found for
HIV [18], with the exception, for HIV, of the association
between an increased perception of being at greater risk of
contamination than the average person and a low level of
knowledge, something which was not found for HBV.
Although HBV can be transmitted sexually (in the same
way as HIV), a large proportion of the general population
were still unaware of this. Only 70% of the respondents
reported that they knew this fact, which is similar to the
percentages found in other European studies: 63% and 78%,
respectively, in Germany and the Netherlands [21]. In con-
trast, transmission by sharing needles when injecting drugs
was better known (90% in our study). Indeed, this differ-
ence in knowledge about these two transmission types has
already been observed in other countries. For example, in
one German study, these values were approximately 60%
for sexual transmission and 95% for transmission through
shared needles during intravenous drug injection [16]. All
these results would suggest that, for a part of the respon-
dents at least, there was some confusion between HBV and
Hepatitis C Virus (HCV), an infection which is principally
transmitted through intravenous drug use and, very rarely,
through sexual relations. The probable difficulty people
have in differentiating between the various types of hepatitis
(described elsewhere [13,14,17]) makes any interpretation
of the indicator “knowledge about hepatitis B transmission
modes” complex. This is also true for the indicator’s associ-
ations with the other variables studied here, including per-
ceptions. The high level of fear reported by the respondentsin our study with respect to viral hepatitis was previously
observed in a French study carried out in 2006 [14].
In the present study, previous screening for HBV dur-
ing one’s lifetime was reported 2.2 times less often than
HIV screening. This is probably an underestimation as,
in France, in 2010, according to the data provided by la-
boratories [22,23], the number of HBV tests performed
was only 1.5 times lower than the number of HIV tests.
Moreover, the proportion of women who had a child less
than one year old and who declared that they had previ-
ously been screened for HBV was low (40%) despite the
fact that such screening - obligatory during pregnancy -
was performed in 87% of women who gave birth in 2009
(from Certificats de Santé du 8ème jour - health certifi-
cates which must be completed before the child is eight
days old – data not published). This last observation may
however be explained by the possible lack of specific in-
formation provided by health professionals to pregnant
women when prescribing HBV screening. In multivariate
analyses, HBV screening was more often declared by those
who perceived themselves to be at higher risk than the
average person, by those born in zones with high HBV en-
demicity, and by those who declared intravenous drug use
in their lifetime. The level of screening reported by the
second and third of these three populations – both target
populations for recommended screening [7,8] – would
nevertheless seem to be very insufficient (45%), despite
possible under-reporting. This value can be compared
with the numbers of French general practitioners in 2009
who reported that they systematically proposed HBV
screening to these same two high risk populations (39%
and 73%, respectively) [24]. Independently of other factors,
in particular educational and income levels, HBV screen-
ing was more frequently reported by inhabitants of Île-de-
France. This trend was also observed in multivariate
analyses for HIV (data not shown) as well as in numbers
of HIV and HBV screening tests performed in laboratories
[22,23] might be linked to a better access to screening in
Île-de-France.
In our study, the proportion of people declaring that
they currently had or that they had previously had hepa-
titis B (3.7%) is coherent with the estimated seroprevalence
of anti-HBc antibodies (7.3%) from a survey performed in
2004 on a random sample of the general French metropol-
itan population if we take into account the proportion of
infected people who were aware of their status (45%) [2].
The proportion of people declaring that they currently had
or that they had previously had hepatitis B was higher in
those who reported intravenous drug use and increased
with the level of HBV endemicity in the country of birth,
which is also in line with the results from the 2004 preva-
lence survey [2].
We found that 47% of the respondents reported being
vaccinated against hepatitis B. This value is very similar
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was carried out in France in 2010 using a similar meth-
odology (48%) (data not published). In multivariate ana-
lysis, anti-HBV vaccination was most often reported by
those people who believed that they were at higher risk
than the average person of being infected. Moreover,
vaccination was more common in the 18–30 year-old
population than in older populations. This result was also
observed in a study in Germany [16]. Indeed, during their
adolescent years between 1995 and 1998, young adults
were the population with the highest proportion of vac-
cination, before vaccination campaigns were stopped in
schools in 1998 [11,25].
The absence of any association between reported vacci-
nation and intermediate or high HBV endemicity in one’s
country of birth as well as between reported vaccination
and reporting intravenous drug use at least once during
one’s lifetime suggests that there is insufficient anti-HBV
vaccination coverage in these populations at highest risk
[6]. This result is in line with data provided from French
mandatory notification of acute hepatitis B which indicated
that at least 53% of reported cases between 2003 and 2011
corresponded to a vaccine indication [25]. This low level
of reported vaccine coverage can be viewed in the light of
the difficulty which French general practitioners have
approaching the subject of drug use with patients (41% in
2009) and in proposing screening before vaccination in
people born in zones of high HBV endemicity [24,26].
Multivariate analyses highlight an association between
educational level and HBV “knowledge of transmission
modes” and “screening and vaccination practices” indica-
tors. Accordingly, they underline the necessity to reduce
social inequalities in health. This is all the more im-
portant since the prevalence of hepatitis B is higher in
individuals in an economically and socially vulnerable
situation [2].
One must be careful when interpreting the results of this
study. As with any self-reported study, certain biases - not-
ably memory bias and social desirability bias - cannot be
excluded. Nevertheless these results show the perception
and the representation of the respondents. The different
types of viral hepatitis are not known very well by quite a
large part of the general population [13,14,16,17,21]. Con-
sequently, any interpretation of the specific values of
knowledge and perception indicators is complex. What is
interesting however is that the values of these indicators
can be compared with those for similar indicators associ-
ated with other diseases (in the present study we did so
with HIV) and can be followed over time. The coherence
between the associations highlighted in the present study
and those which have been found elsewhere (for example
the higher reported prevalence of HBV infection in
persons at highest risk) strengthens the validity of our
results. Finally, in this study, the participation rate(about 66%) was rather good and close to those ob-
served in other random sampling telephone surveys
[27] and data were adjusted for socio-demographic
data (age, gender, living in couple and professional
activity). However, some people were certainly under-
represented, in particular migrants in the most
vulnerable economic and social situations (given that
being a French speaker was one of the criteria for
eligibility) and consequently it is possible that the
reported prevalence of infection was underreported
[2].
Conclusions
This study provided, for the first time in France, quanti-
tative data on the knowledge, perceptions and practices
of the general population with respect to hepatitis B. It
highlights a lower level of knowledge about the disease
together with less screening in the general population
when compared to HIV. Furthermore, it suggests that
there is confusion in the general population about the
differences between hepatitis B and C. More widely, al-
though France is known to be the country with the best
hepatitis care delivery in Europe [28], improvement is
needed, in particular concerning HBV screening. Indeed,
55% of HBV-infected persons were unaware of their
status in general population in 2004, this proportion
reaching 80% among individuals born in high HBV
endemic countries (Asia, Sub Saharan Africa) among
whom HBV prevalence was estimated at 4% [2].
In comparison, about 19% of persons living with
HIV were undiagnosed [29]. Moreover, despite recent
progress in HBV vaccine coverage in toddlers,
situation is still critical for teenagers aged of 15 years
(< 50%) who will begin their sexual life [12]. All these
results demonstrate that there is room for improve-
ment in HBV, notably in comparison to HIV.
The results of the present study should prove useful
for interventions targeted at healthcare professionals and
for future information and prevention campaigns directed
at the general population and populations at highest risk
of HBV [24,26] even if communication is not sufficient in
itself [30]. It would certainly seem important to improve
public understanding of the specificities of both hepatitis
B and C in order to contribute to improvement of screen-
ing and vaccination practices.
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